Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 11/20 | 0.53 |
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182882 | 0.89 | SMN1; SMN2 (0.58) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL29263828 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2C19NPSR1NPC1RAB9A | |
| SCHEMBL20939584 | 0.78 | DYRK1A (0.47) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL28332239 | 0.78 | KCNH2 (0.38) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL24777901 | 0.77 | ADRA2A (0.61) | CYP1A2CYP2C19NPSR1NPC1RAB9A | |
| SCHEMBL19669661 | 0.76 | TRPV1 (0.49) | CYP1A2CYP2C19NPSR1MAPTGAA | |
| SCHEMBL3227014 | 0.74 | CYP1A2 (0.70) | CYP1A2CYP2C19NPSR1NPC1RAB9A | |
| SCHEMBL20040871 | 0.74 | BRAF (0.41) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13241 | 0.74 | CYP1A2 (0.55) | CYP1A2CYP2C19NPSR1NPC1RAB9A | |
| SCHEMBL1147541 | 0.74 | CYP1A2 (0.59) | CYP1A2CYP2C19NPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| CN-109082886-B | Thiosemicarbazide molecule covalent grafting acrylic fiber, preparation method and application | 武汉纺织大学 | 2021-05-07 | — | — | CN | disclosed |
| WO-2015021943-A9 | INDUCING NEUROGENESIS BY AXIN ENHANCER | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015021943-A1 | INDUCING NEUROGENESIS BY AXIN ENHANCER | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-02-19 | — | — | WO | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CYP1A2 1230/4885CYP2C19 1491/4885NPSR1 8/4885 |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | CYP1A2 1471/4885CYP2C19 1685/4885NPSR1 1565/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | CYP1A2 876/4885CYP2C19 1651/4885NPSR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.